博济医药：子公司广州华圣制药获药品注册证书

Core Viewpoint - The approval of "Compound Polyethylene Glycol Electrolyte Powder (III)" by the National Medical Products Administration indicates a significant advancement for the company in the pharmaceutical market, particularly for bowel preparation in adults undergoing endoscopic or radiological examinations and colon surgeries [1] Company Summary - The subsidiary Guangzhou Huasheng Pharmaceutical Co., Ltd. has received the drug registration certificate for "Compound Polyethylene Glycol Electrolyte Powder (III)" [1] - This drug is specifically designed for bowel cleansing preparation in adult patients prior to endoscopic or radiological examinations and colon surgeries [1] Market Potential - According to data from Minet, the sales scale of "Compound Polyethylene Glycol Electrolyte Powder (III)" in urban and county-level public hospitals in China is approximately 220 million RMB in 2024 [1] - The approval signifies that the drug meets the national pharmaceutical review technical standards and can be produced and sold in the domestic market upon compliance with production quality management regulations [1]